Initial studies on patients with relapsed DLBCL treated with anti-CD20 or anti-CD19 CAR T cells were not very successful, most likely due to a cellular anti-transgene immune response in some of the patients [443, 455]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.